Dr. Amir Fathi, MD
Claim this profileMassachusetts General Hospital
Expert in Acute Myeloid Leukemia
Expert in T-Lymphoblastic Leukemia/Lymphoma
15 reported clinical trials
20 drugs studied
Area of expertise
1Acute Myeloid Leukemia
Global LeaderFLT3 positive
IDH positive
Stage IV
2T-Lymphoblastic Leukemia/Lymphoma
Global LeaderFLT3 positive
IDH positive
Stage IV
Affiliated Hospitals
Clinical Trials Amir Fathi, MD is currently running
REM-422
for Acute Myeloid Leukemia and Higher Risk MDS
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML
Recruiting1 award Phase 1
Venetoclax + Azacitidine
for Acute Myeloid Leukemia
This research is being done to assess the therapeutic activity of a promising combination (azacitidine and venetoclax) versus conventional cytotoxic chemotherapy in induction-eligible patients with acute myeloid leukemia. This study involves the following: * Venetoclax and azacitidine (investigational combination) * Cytarabine and idarubicin or daunorubicin (per standard of care) or Liposomal daunorubicin and cytarabine (per standard of care)
Recruiting1 award Phase 24 criteria
More about Amir Fathi, MD
Clinical Trial Related2 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Amir Fathi, MD has experience with
- Venetoclax
- Azacitidine
- Daunorubicin
- Ivosidenib
- Gilteritinib
- Midostaurin
Breakdown of trials Amir Fathi, MD has run
Acute Myeloid Leukemia
T-Lymphoblastic Leukemia/Lymphoma
Myeloid Leukemia
Acute Myelogenous Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Amir Fathi, MD specialize in?
Amir Fathi, MD focuses on Acute Myeloid Leukemia and T-Lymphoblastic Leukemia/Lymphoma. In particular, much of their work with Acute Myeloid Leukemia has involved FLT3 positive patients, or patients who are IDH positive.
Is Amir Fathi, MD currently recruiting for clinical trials?
Yes, Amir Fathi, MD is currently recruiting for 8 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Amir Fathi, MD has studied deeply?
Yes, Amir Fathi, MD has studied treatments such as Venetoclax, Azacitidine, Daunorubicin.
What is the best way to schedule an appointment with Amir Fathi, MD?
Apply for one of the trials that Amir Fathi, MD is conducting.
What is the office address of Amir Fathi, MD?
The office of Amir Fathi, MD is located at: Massachusetts General Hospital, Boston, Massachusetts 02214 United States. This is the address for their practice at the Massachusetts General Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.